Search
Sodium aurothiomalate
go.drugbank.com/drugs/DB09276ApprovedWithdrawnIt is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedThe drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. … In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer.
Categories: Analgesics, Non-NarcoticEtesevimab
go.drugbank.com/drugs/DB15897Investigationalprogressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for
Betaprodine
go.drugbank.com/drugs/DB01473ExperimentalIllicitAn opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.
N4-Hydroxycytidine
go.drugbank.com/drugs/DB15660Experimental[A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. … [A193026] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.
Synonyms: 4-N-Hydroxycytidine, N(4)-HydroxycytidineRivoglitazone
go.drugbank.com/drugs/DB09200InvestigationalIt is being developed by Daiichi Sankyo Co.
GLP-1 (7-36) amide
go.drugbank.com/drugs/DB19258InvestigationalGLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … The Company determined that the program was not meeting their expected primary and exploratory objectives.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.